The cell cycle is an important part of cell life. Studies have found that the occurrence of various malignant tumors is closely related to the disorder of cell cycle regulation mechanism, so tumor is also considered as a cell cycle disease. Cyclin dependent kinase (CDK) promotes the orderly progression of the cell cycle, so cyclin dependent kinase inhibitors (CDKI) block the cell cycle and control cell proliferation, resulting in anti-tumor activity.
CDK is a serine/threonine kinase with short n-terminal and long C-terminal, and its ATP-binding pocket is located between n-terminal and c-terminal. CDK functions at all stages of the cell cycle, promoting orderly cell proliferation. Unlike other kinases, CDK must bind to cyclins to function. The periodic expression and degradation of cyclin promote the orderly progress of cell cycle and cause cell growth and proliferation.

CDKI works by competitively binding ATP binding regions of CDK, which can effectively prevent cell proliferation or promote cell apoptosis. At present, some researches on CDKI have entered clinical stage.
According to the different selectivity of CDKI to target enzymes, it can be divided into three categories:
(1)broad-spectrum CDKI can prevent cell from G1 phase to S phase and G2 to M phase transition, at the same time can interfere with the RNA polymerase Ⅱ role in transcription process.
(2) Specific CDKI is a small molecule with high selectivity, which can inhibit CDK2/cyclinA. The specific mechanism of CDKI is to block cell cycle by inhibiting gene transcription.
(3) CDK inhibitors with other kinase activities have been found in the treatment of non-small cell carcinoma to effectively inhibit the proliferation of tumor cells. The mechanism of anticancer effect may be based on the influence on the repair mechanism of DNA double-strand fracture.
CDK inhibitors have promising prospects for the treatment of human cancer. Although selective CDKI has shown excellent anti-proliferation effect in clinical trials, it is still a big problem to choose CDKI for different tumor treatments.
E9387h is a ready-to-use microwell, strip plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the A Disintegrin and Metalloprotease 30 (Cyclin-dependent kinase inhibitor 1) ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing Cyclin-dependent kinase inhibitor 1. The ELISA analytical biochemical technique of the E9387h kit is based on Cyclin-dependent kinase inhibitor 1 antibody-Cyclin-dependent kinase inhibitor 1 antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect Cyclin-dependent kinase inhibitor 1 antigen targets in samples
Product link:
http://www.eiaab.com/entries/detail/CDN1A_HUMAN